Brief report of efficacy and side effect profile of crossing over to modified-release capsules of methylphenidate in ADHD patients receiving other treatments: case series

Figures & data

Table 1. Comorbid diagnoses of patients.

		Count	Of total sample (%)
Comorbid diagnoses	Anxiety disorder	8	40
	ODD	3	15
	OCD	2	10
	MDD	3	15
	Tic disorder	1	5
	EN	1	5
	ASD^a	1	5
	Learning disorder	1	5

Note: OCD, obsessive-compulsive disorder; ODD, oppositional defiance disorder; MDD, major depressive disorder; EN, enuresis nocturna; ASD, autism spectrum disorder.

^aAtypical autism with high functionality.

Figure 1. Patient selection and flow chart.

Table 2. Summary of the first-line treatment data.

		IR-MPH (n = 19)	OROS-MPH (n = 1)
		count	count
Side effects	Loss of appetite	3	1
	Tics	2	1
	Drowsiness	1	0
	Headache	1	0
	Dryness of the mouth	1	0
	Epistaxis	1	0
	Irritability	1	0
Treatment response	No	1	1
	Yes	16	0
	Partially	2	0
Reasons for drug switch	Poor compliance	15	0
	Side effect	2	0
	Poor response	2	1

Table 3. Summary of the second-line treatment data.

		IR-MPH (n = 1)	OROS-MPH (n = 17)	MRC-MPH (n = 2)
		count	count	count
Side effects	Loss of appetite	0	8	0
	Tics	1	1	0
	Drowsiness	0	2	0
	Headache	0	1	0
	Stomach ache	0	2	0
	Thoracic pain	0	2	0
	Nausea	0	2	0
	Anxiety	0	1	0
	Irritability	0	1	0
Treatment response	No	0	1	0
	Yes	1	13	1
	Partially	0	3	1
Reasons for drug switch	Poor compliance	1	0	0
	Side effect	0	13	0
	Poor response	0	4	0

Note: IR-MPH, immediate-release methylphenidate; OROS-MPH, osmotic-release oral system methylphenidate; MRC-MPH, modified-release capsule methylphenidate.

Table 4. Summary of the third-line treatment data.

		ATX (n = 5)	OROS-MPH and ATX (n = 2)
		count	count
Side effects	Headache	2	0
	Thoracic pain	1	0
	Nausea	1	1
	Dizziness	1	1
Treatment response	No	4	1
	Yes	0	0
	Partially	1	1
Reasons for drug switch	Poor compliance	0	1
	Side effect	3	0
	Poor response	2	1

Note: OROS-MPH, osmotic-release oral system methylphenidate; ATX, atomoxetine.

Table 5. Side effects of MRC-MPH treatment.

		MRC-MPH 20 mg (n = 3)	MRC-MPH 30 mg (n = 7)	MRC-MPH 40 mg (n = 10)
		count	count	count
Side effects	Loss of appetite	1	2	1
	Drowsiness	0	3	1
	Irritability	0	0	2
	Dizziness	0	0	1

Note: MRC-MPH, modified-release capsule methylphenidate.